Cargando…

VKORC1 and CYP2C9 Polymorphisms: A Case Report in a Dutch Family with Pulmonary Fibrosis

Here, we describe a Dutch family with idiopathic pulmonary fibrosis (IPF). We hypothesized that there might be an association between the presence of Vitamin K epoxide reductase complex 1 (VKORC1) and/or cytochrome P450 2C9 (CYP2C9) variant alleles and the early onset of IPF in the members of this f...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wijnen, Petal, Drent, Marjolein, Bekers, Otto, Verschakelen, Johny, Bast, Aalt
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6429271/ https://www.ncbi.nlm.nih.gov/pubmed/30866412 http://dx.doi.org/10.3390/ijms20051160

Ejemplares similares

Tamsulosin Associated with Interstitial Lung Damage in CYP2D6 Variant Alleles Carriers
por: Jessurun, Naomi T., et al.
Publicado: (2020)

Drug-induced comorbidities in patients with sarcoidosis
por: Drent, Marjolein, et al.
Publicado: (2022)

Role of Drug–Gene Interactions and Pharmacogenetics in Simvastatin-Associated Pulmonary Toxicity
por: Jessurun, Naomi T., et al.
Publicado: (2021)

Increased circulating desmosine and age-dependent elastinolysis in idiopathic pulmonary fibrosis
por: de Brouwer, Bart, et al.
Publicado: (2018)

A predictive tool for an effective use of (18)F-FDG PET in assessing activity of sarcoidosis
por: Mostard, Rémy LM, et al.
Publicado: (2012)

Polymorphism of the CYP2C9 and VKORC1 genes: a comment
por: Mungmunpuntipantip, Rujittika, et al.
Publicado: (2021)

Polymorphisms of VKORC1 and CYP2C9 are associated with warfarin sensitivity in Chinese population
por: Jia, LiQun, et al.
Publicado: (2017)

Self-reported Gastrointestinal Side Effects of Antifibrotic Drugs in Dutch Idiopathic Pulmonary Fibrosis patients
por: Proesmans, V. L. J., et al.
Publicado: (2019)

Prosthetic valve thrombosis – association of genetic polymorphisms of VKORC1, CYP2C9 and CYP4F2 genes
por: SR, Kalpana, et al.
Publicado: (2019)

Identification of CYP2C9 and VKORC1 polymorphisms in Iranian patients who are under warfarin therapy
por: Poopak, Behzad, et al.
Publicado: (2015)

VKORC1 and CYP2C9 polymorphisms related to adverse events in case-control cohort of anticoagulated patients
por: Misasi, Silvia, et al.
Publicado: (2016)

Effects of CYP2C9 and VKORC1 polymorphisms on warfarin sensitivity and responsiveness during the stabilization phase of therapy
por: AL-Eitan, Laith N., et al.
Publicado: (2019)

The effect of CYP2C9 and VKORC1 genetic polymorphisms on warfarin dose requirements in a pediatric population
por: Taşkın, Birce Dilge, et al.
Publicado: (2016)

The allele frequency of CYP2C9 and VKORC1 in the Southern Khorasan population
por: Razavi, Fariba Emadian, et al.
Publicado: (2017)

Genetic polymorphisms in warfarin and tacrolimus-related genes VKORC1, CYP2C9 and CYP3A5 in the Greek-Cypriot population
por: Hadjipanagi, Despina, et al.
Publicado: (2014)

Polymorphism of the CYP2C9 and VKORC1 genes in patients on the public health system of a municipality in Southern Brazil
por: Colet, Christiane, et al.
Publicado: (2021)

CYP4F2 and VKORC1 Polymorphisms Amplify the Risk of Carotid Plaque Formation
por: Vesa, Stefan Cristian, et al.
Publicado: (2020)

Frequency distribution of polymorphisms of CYP2C19, CYP2C9, VKORC1 and SLCO1B1 genes in the Yakut population
por: Vasilyev, Filipp Filippovich, et al.
Publicado: (2016)

Analysis of CYP2C9*2, CYP2C9*3 and VKORC1 -1639 G>A polymorphisms in a population from South-Eastern Europe
por: Buzoianu, Anca D, et al.
Publicado: (2012)

The effect of CYP2C9*2, CYP2C9*3, and VKORC1-1639 G>A polymorphism in patients under warfarin therapy in city of Kermanshah
por: Hosseinkhani, Zohreh, et al.
Publicado: (2018)

Polymorphisms of CYP2C9*2, CYP2C9*3 and VKORC1 genes related to time in therapeutic range in patients with atrial fibrillation using warfarin
por: da Silveira, Maria Mariana Barros Melo, et al.
Publicado: (2019)

Impact of CYP2C9 and VKORC1 Polymorphisms on Warfarin Sensitivity and Responsiveness in Jordanian Cardiovascular Patients during the Initiation Therapy
por: AL-Eitan, Laith N., et al.
Publicado: (2018)

Phenprocoumon Dose Requirements, Dose Stability and Time in Therapeutic Range in Elderly Patients With CYP2C9 and VKORC1 Polymorphisms
por: Schneider, Katharina Luise, et al.
Publicado: (2020)

Frequency of polymorphisms in the CYP2C9, VKORC1, and CYP4F2 genes related to the metabolism of Warfarin in healthy donors from Cali, Colombia
por: Giraldo-Ocampo, Sebastian, et al.
Publicado: (2023)

Prevalence of interstitial and other lung diseases on Aruba
por: Deenstra, Duco, et al.
Publicado: (2017)

Genotyping of CYP2C9 and VKORC1 in the Arabic Population of Al-Ahsa, Saudi Arabia
por: Alzahrani, Abdullah M., et al.
Publicado: (2013)

Association between genetic polymorphisms of CYP2C9 and VKORC1 and safety and efficacy of warfarin: Results of a 5 years audit
por: Biswas, Mansij, et al.
Publicado: (2018)

Warfarin dose and INR related to genotypes of CYP2C9 and VKORC1 in patients with myocardial infarction
por: Haug, Kari Bente Foss, et al.
Publicado: (2008)

VKORC1 and CYP2C9 Genotype Variations in Relation to Warfarin Dosing in Korean Stroke Patients
por: Park, Sea Mi, et al.
Publicado: (2013)

Evaluation of CYP2C9- and VKORC1-based pharmacogenetic algorithm for warfarin dose in Gaza-Palestine
por: Ayesh, Basim Mohammad, et al.
Publicado: (2018)

Impact of CYP2C9, VKORC1 and CYP4F2 genetic polymorphisms on maintenance warfarin dosage in Han-Chinese patients: A systematic review and meta-analysis
por: Zhang, Jinhua, et al.
Publicado: (2016)

Testing of VKORC1 and CYP2C9 alleles to guide warfarin dosing: Test Category: Pharmacogenomic (Treatment)
por: Grossniklaus, Daurice
Publicado: (2010)

Influence of CYP2C9 and VKORC1 on Patient Response to Warfarin: A Systematic Review and Meta-Analysis
por: Jorgensen, Andrea L., et al.
Publicado: (2012)

Warfarin Dosing in a Patient with CYP2C9(∗)3(∗)3 and VKORC1-1639 AA Genotypes
por: Johnson, Mark, et al.
Publicado: (2014)

Determination of Pleiotropic Effect of Warfarin in VKORC1 and CYP2C9 Genotypes in Patients With Heart Valve Replacement
por: Shafique, Huma, et al.
Publicado: (2022)

The Contribution of VKORC1 and CYP2C9 Genetic Polymorphisms and Patients’ Demographic Characteristics with Warfarin Maintenance Doses: A Suggested Warfarin Dosing Algorithm
por: Khaleqsefat, Esmat, et al.
Publicado: (2020)

VKORC1 and Novel CYP2C9 Variation Predict Warfarin Response in Alaska Native and American Indian People
por: Henderson, Lindsay M., et al.
Publicado: (2019)

A Genome-Wide Association Study Confirms VKORC1, CYP2C9, and CYP4F2 as Principal Genetic Determinants of Warfarin Dose
por: Takeuchi, Fumihiko, et al.
Publicado: (2009)

The role of CYP2C9*2, CYP2C9*3 and VKORC1-1639 variants on the susceptibility of upper gastrointestinal bleeding: A full case-control study
por: Forgerini, Marcela, et al.
Publicado: (2023)

Effect of CYP2C9, VKORC1, and CYP4F2 polymorphisms on warfarin maintenance dose in children aged less than 18 years: a protocol for systematic review and meta-analysis
por: Takeuchi, Masanobu, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_gtcbvafrbncs3mai01jbkbt6ga